ABLYNX TO PRESENT AT THE 32nd ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE AND TO PROVIDE AN UPDATE ON ITS TTP PROGRAMME Print
By GLOBE NEWSWIRE   
Sunday, 12 January 2014 19:44

GHENT, Belgium, Jan. 13, 2014 (GLOBE NEWSWIRE)

GHENT, Belgium, Jan. 13, 2014 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] today announced that it will present at the 32nd Annual J.P. Morgan Healthcare Conference on Thursday 16 January 2014, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time).

Dr Edwin Moses, CEO of Ablynx, will give a corporate presentation that will include an update on the Company's anti-vWF Nanobody, caplacizumab, to treat acquired thrombotic thrombocytopenic purpura (TTP), a rare blood disorder. Some improvement in recruitment has been seen since amending the clinical protocol in September 2013, nevertheless, Ablynx has decided to stop recruitment of the trial now to allow earlier analysis of the data for potential proof-of-concept. Phase II data are now expected during the first half of 2014 and if the results are promising, a Phase III study is anticipated to commence in 2015.

The slides may be accessed via the Company's website, www.ablynx.com, under the 'News and Events>upcoming events' section.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 30 programmes in the pipeline and seven Nanobodies in clinical development. Ablynx has on-going research collaborations and significant partnerships with major pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Merck & Co, Merck Serono and Novartis. The Company is headquartered in Ghent, Belgium.

More information can be found on www.ablynx.com.

For more information, please contact

Ablynx:

Dr Edwin Moses
CEO
t:   +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
     +32 (0)473 39 50 68
e:  edwin.moses@ablynx.com

Marieke Vermeersch
Associate Director Investor Relations
t:   +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e:  marieke.vermeersch@ablynx.com
Follow us on Twitter @AblynxABLX

Ablynx media relations Consilium Strategic Communications:

Mary-Jane Elliott, Amber Bielecka, Lindsey Neville
t:   +44 207 920 2345
e:  ablynx@consilium-comms.com

pdf version of the press release http://hugin.info/137912/R/1754015/591769.pdf

HUG#1754015




BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and
investor relation services from various entities and

Error. Page cannot be displayed. Please contact your service provider for more details. (6)

firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
  BMR:1